RIDR-PI-103 是一种活性氧 (ROS) 诱导的药物释放前药，具有与泛 PI3K 抑制剂 (PI-103) 连接的自环化部分。Doxorubicin 和 RIDR-PI-103 在 MDA-MB-361 和 MDA-MB-231 细胞中显示出抑制癌细胞增殖的协同作用。

RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation [1] [2].

2581114-71-6

C27H25N7O4

511.53

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years